stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Net margin
Roivant Sciences Ltd.'s net margin over the twelve months to 30 June 2026 was −3,535.0%, up 94.2 percentage points from fiscal 2026 (−3,629.2%). Over the past ten years it has ranged from −3,629.2% (fiscal 2026) to 13,294.2% (fiscal 2024) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | −3,629.2% | (3,037.23) |
| FY2025 | −592.0% | (13,886.14) |
| FY2024 | 13,294.2% | 14,940.77 |
| FY2023 | −1,646.6% | (117.70) |
| FY2022 | −1,528.9% | 1,871.97 |
| FY2021 | −3,400.9% | (3,400.86) |
| FY2020 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −13,164.8% | (25,188.41) |
| Mar 2026 | 12,023.6% | 25,324.77 |
| Dec 2025 | −13,301.2% | (6,075.29) |
| Sep 2025 | −7,225.9% | 3,066.95 |
| 21 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 52.9% |
| GMAB Genmab A/S Sponsored ADR compare | 19.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 13.9% |
| INCY Incyte Corporation compare | 6.71% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| INSM Insmed, Inc. compare | −39.9% |
| BNTX BioNTech SE Sponsored ADR compare | −63.8% |
| RVMD Revolution Medicines, Inc. compare | −894.4% |
| ROIV Roivant Sciences Ltd. | −3,535.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement